Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin in relapsed or refractory AL amyloidosis
2024-513075-40-00Phase 2Completed
- Sponsor
- European Myeloma Network
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in light-chain amyloidosis, sponsored by European Myeloma Network. Primary endpoint: CR/VGPR/low-dFLC response rate at 6 months. Started Aug 2024; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2024-513075-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513075-40-00.